Cardiovascular Drugs and Therapy

, Volume 14, Issue 1, pp 61–66 | Cite as

Guanabenz Combination Therapy Inhibits Sympathetic Nerve Activity and Regresses Left Ventricular Hypertrophy

  • Eiji Miyajima
  • Tomohiko Shigemasa
  • Tsutomu Endo
  • Satoru Hishiki
  • Yoshiyuki Kawano


The cardiovascular and sympatholytic effects of combination therapy with guanabenz were examined in 26 patients (48 ± 13 years old [mean ± SD]) with stage 2 and 3 hypertension. Included in the study were patients under treatment with conventional antihypertensive drugs whose systolic and diastolic blood pressure was above 140 and 90 mmHg, respectively. Blood pressure, heart rate, and sympathetic parameters such as plasma concentration of norepinephrine and muscle sympathetic nerve activity at rest as well as during ambulatory conditions, 24-hour urinary excretion of norepinephrine, and low frequency (LF: 0.04–0.15 Hz)/high frequency (HF: 0.15–0.4 Hz) power ratio as a marker of cardiac sympathetic activity during 24 hours were examined before and after guanabenz (4–8 mg/d) combination therapy with first-line antihypertensive drugs such as diuretics. Left ventricular mass index (LVMI) was also calculated by conventional echocardiography. After 32 weeks of guanabenz combination therapy, systolic and diastolic blood pressure, heart rate, plasma and urinary excretion of norepinephrine, muscle sympathetic nerve activity, and LF/HF power ratio were significantly decreased, while neither LF nor HF power was changed. LVMI was also significantly decreased (270 ± 81 vs. 236 ± 83 g/m2, p < 0.005). These results indicate that guanabenz combination therapy inhibits sympathetic nerve activity under resting conditions as well as during ambulatory conditions and may accelerate regression of left ventricular hypertrophy in patients with moderate to severe hypertension.

α2-agonist essential hypertension heart rate variability muscle sympathetic nerve activity norepinephrine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.Google Scholar
  2. 2.
    Miyajima E, Yamada Y, Matsukawa T, Tochikubo O, Ishii M, Kaneko Y. Neurogenic abnormalities in young borderline hypertensives. Clin Exp Hypertens 1988;A10(Suppl.1):209-223.Google Scholar
  3. 3.
    Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 1989;13:870-877.Google Scholar
  4. 4.
    Miyajima E, Yamada Y, Yoshida Y, et al.Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991;17:1057-1062.Google Scholar
  5. 5.
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH publication No. 98-4080. Washington, DC: NIH, 1997.Google Scholar
  6. 6.
    Wollam GL, Hall WD, Porter VD, et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983;75:100-110.Google Scholar
  7. 7.
    Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-178.Google Scholar
  8. 8.
    Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.Google Scholar
  9. 9.
    Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-1793.Google Scholar
  10. 10.
    Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertension 1995;13:1091-1095.Google Scholar
  11. 11.
    Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest 1983;72:732-738.Google Scholar
  12. 12.
    Pegram BL, Frohlich ED. Cardiovascular adjustment to antiadrenergic agents. Am J Med 1983;75:94-99.Google Scholar
  13. 13.
    Tarazi RC. Regression of left ventricular hypertrophy by medical treatment: present status and possible implications. Am J Med 1983;75(Suppl. 3A):80-86.Google Scholar
  14. 14.
    Timio M, Venanzi S, Gentili S, Ronconi M, Del Re G, Del Vita M. Reversal of left ventricular hypertrophy after one-year treatment with clonidine: relationship between echocardiographic findings, blood pressure, and urinary catecholamines. J Cardiovasc Pharmacol 1987;10(Suppl. 12):s142-s146.Google Scholar
  15. 15.
    Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977;11:427-433.Google Scholar
  16. 16.
    Long CS, Kariya K, Karns L, Simpson PC. Sympathetic activity: Modulator of myocardial hypertrophy. J Cardiovasc Pharmacol 1991;172:s20-s24.Google Scholar
  17. 17.
    Marcus R, Krause L, Weder AB, Mejia AD, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study. Circulation 1994;90:928-936.Google Scholar
  18. 18.
    Tan SA, Berk LS, Tan LG. Indapamide regresses, but transdermal clonidine does not regress, left ventricular hypertrophy in hypertensive diabetic patients. Am J Cardiol 1996; 77:20B-22B.Google Scholar
  19. 19.
    Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. Am J Hypertens 1992;5:95-110.Google Scholar
  20. 20.
    Kleine P, Meissner E, von Bruchhausen V, Bruckner S. Effects of clonidine and nifedipine on left ventricular hypertrophy and muscle mass in hypertensive patients. J Cardiovasc Pharmacol 1987;10(Suppl. 12):s180-186.Google Scholar
  21. 21.
    Strauer BE. Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol 1988;12(Suppl. 4):S45-S54.Google Scholar
  22. 22.
    Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1983;26: 212-229.Google Scholar
  23. 23.
    Guidelines Sub-committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Heath Organization/International Society of Hypertension meeting. J Hypertens 1993;11:905-918.Google Scholar
  24. 24.
    Ohtomo N, Sumi A, Tanaka, Y, Tokiwano, K, Terachi S. A detailed study of power spectral density for Rossler system. J Phys Soc Jpn 1996;65:2811-2823.Google Scholar
  25. 25.
    Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation 1977;55: 613-618.Google Scholar
  26. 26.
    Nohta H, Mitsui A, Okura Y. Spectrofluorometric determination of catecholamines with 1,2-diphenylendiamine. Anal Chim Acta 1984;165:171-176.Google Scholar
  27. 27.
    Kaplan JR, Pettersson K, Manuck SB, Olsson G. Role of sympathoadrenal medullary activation in the initiation and progression of atherosclerosis. Circulation 1991;846:VI23-VI32.Google Scholar
  28. 28.
    Dibona GF. Sympathetic neural control of the kidney in hypertension. Hypertension 1992;191:128-135.Google Scholar
  29. 29.
    Rosen MR, Danilo P Jr, Robinson RB, Shah A, Steinberg SF. Sympathetic neural and α-adrenergic modulation of arrhythmias. Ann N Y Acad Sci 1988;533:200-209.Google Scholar
  30. 30.
    Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987;60:560-565.Google Scholar
  31. 31.
    Hartford M, Wilkstrand J, Wallentin I, Ljungman S, Berglund G. The relation between cardiac hypertrophy and hypertension. Acta Med Scand 1983;(Suppl 672):101-104.Google Scholar
  32. 32.
    DiBona GF, Jones SY, Sawin LL. Renal sympathetic neural mechanisms as intermediate phenotype in spontaneously hypertensive rats. Hypertension 1996;27:626-630.Google Scholar
  33. 33.
    Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997;95:1983-1985.Google Scholar
  34. 34.
    Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.Google Scholar
  35. 35.
    Gehr M, MacCarthy P, Goldberg M. Guanabenz. A centrally acting, natriuretic antihypertensive drug. Kidney Int 1986; 29:1203-1208.Google Scholar
  36. 36.
    Regunathan S, Youngson C, Raasch W, Wang H, Reis DJ. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. J Pharmacol Exp Ther 1996;276:1272-1282.Google Scholar
  37. 37.
    Dorman T, Clarkson K, Rosenfeld BA, Shanholtz C, Lipsett PA, Breslow MJ. Effects of clonidine on prolonged postoperative sympathetic response. Crit Care Med 1997;25:1147-1152.Google Scholar
  38. 38.
    Stuhmeier KD, Mainzer B, Cierpka J, Sandmann W, Tarnow J. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology 1996;85:706-712.Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Eiji Miyajima
    • 1
  • Tomohiko Shigemasa
    • 2
  • Tsutomu Endo
    • 2
  • Satoru Hishiki
    • 2
  • Yoshiyuki Kawano
    • 2
  1. 1.Yokohama City University School of Medicine, Medical CenterYokohamaJapan
  2. 2.Yokohama City University School of Medicine, Medical CenterYokohamaJapan

Personalised recommendations